Boehringer Ingelheim’s Dabigatran Demonstrates Non-Inferiority To Lovenox
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker is in discussions with U.S. regulators regarding submission for venous thromboembolism, but has not released a filing timeline.
You may also be interested in...
Heart Attack Signal Is Likely Focus For Panel Review Of Boehringer Ingelheim's Pradaxa
When FDA's Cardiovascular and Renal Drugs Advisory Committee meets Sept. 20 to consider Boehringer Ingelheim's Pradaxa (dabigatran) for stroke prevention, a significantly higher rate of heart attacks among clinical trial patients compared with warfarin is likely to come up.
Heart Attack Signal Is Likely Focus For Panel Review Of Boehringer Ingelheim's Pradaxa
When FDA's Cardiovascular and Renal Drugs Advisory Committee meets Sept. 20 to consider Boehringer Ingelheim's Pradaxa (dabigatran) for stroke prevention, a significantly higher rate of heart attacks among clinical trial patients compared with warfarin is likely to come up.
Atrial Fibrillation Data For Boehringer Ingelheim’s Dabigatran Due In Early 2009
Firm completes enrollment in RE-LY trial, one of seven in the Phase III RE-VOLUTION program for the investigational antithrombotic.